FDA clears MRI-based AI for mild cognitive impairment prognosis and Elucid's FFR-IQ
The FDA cleared an MRI-based AI software on 20 October for the prognostic assessment of patients with mild cognitive impairment. Elucid's FFR-IQ also received 510(k) clearance, a cardiovascular imaging AI that combines plaque biology and hemodynamics.
Who is affected and how
- doctor
- Neurologists and cardiologists may gain new AI-based prognostic and functional imaging tools.
- medtech company
- The 510(k) clearances signal a path for further categories of imaging AI.
Sources
- FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairmentdiagnostic imaging · Oct 20, 2026
- NeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive Impairmenttmcnet.com · Oct 20, 2026
- Korea's NeuroXT receives US FDA 510(k) clearance for AI software supporting prognostic assessment in Mild Cognitive Impairmentbiospectrum asia · Oct 21, 2026
- Elucid Scores FDA Clearance for FFR-IQ to Unify Plaque Biology and Hemodynamics - HIT Consultanthitconsultant.net · Oct 21, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.